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3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is being investigated in MDMA-
assisted psychotherapy. The present study characterized the safety pharmacology of single-
dose administrations of MDMA (75 or 125 mg) using data from nine double-blind, placebo-
controlled, crossover studies performed in the same laboratory in a total of 166 healthy 
subjects. The duration of the subjective effects was 4.2±1.3 h (range: 1.4-8.2 h). The 125 mg 
dose of MDMA produced greater “good drug effect” ratings than 75 mg. MDMA produced 
moderate and transient “bad drug effect” ratings, which were greater in women than in men. 
MDMA increased systolic blood pressure to >160 mmHg, heart rate >100 beats/min, and 
body temperature >38°C in 33%, 29%, and 19% of the subjects, respectively. These 
proportions of subjects with hypertension (>160 mmHg), tachycardia, and body temperature 
>38°C were all significantly greater after 125 mg MDMA compared with the 75 mg dose. 
Acute and subacute adverse effects of MDMA as assessed by the List of Complaints were 
dose-dependent and more frequent in females. MDMA did not affect liver or kidney function 
at the end of the study 29±22 days after use. No serious adverse events occurred. In 
conclusion, MDMA produced predominantly acute positive subjective drug effects. Bad 
subjective drug effects and other adverse effects were significantly more common in women. 
MDMA administration was overall safe in physically and psychiatrically healthy subjects and 
in a medical setting. However, the risks of MDMA are likely higher in patients with 
cardiovascular disease and remain to be investigated in patients with psychiatric disorders. 
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Introduction 
 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is used recreationally and 
investigated clinically as a medication in MDMA-assisted psychotherapy in patients with 
posttraumatic stress disorder (PTSD; (Amoroso and Workman, 2016; Sessa and Nutt, 2015; 
Mithoefer et al., 2010; Mithoefer et al., 2016; Oehen et al., 2013; Kupferschmidt, 2014). The 
future use of MDMA in psychiatric practice will depend on its efficacy in specific disorders 
and its safety of use. The benefits and harms associated with MDMA have been previously 
discussed (Parrott, 2013a; Doblin et al., 2014; Parrott, 2014). Currently, however, sufficient 
data from clinical Phase I-III studies have not been published in peer-reviewed journals. 
Phase III studies are currently being planned (MAPS, 2016), and more information on the 
clinical safety of MDMA is needed (Mithoefer et al., 2016). Therefore, the present study 
sought to provide data on the safety pharmacology of single-dose administrations of MDMA. 
We primarily addressed the acute effects during the MDMA response (0-6 h) and the sub-
acute adverse effects up to 24 h after the administration of MDMA. We also included data on 
any adverse events that occurred during the entire clinical studies including blood laboratory 
values obtained at the end of study visit. These data were collected from a series of Phase I 
clinical studies that were conducted in our laboratory and used the same standardized data 
recording methods. These studies used one or two single-dose administrations of MDMA at 
doses equal or similar to those used in MDMA-assisted psychotherapy (Mithoefer et al., 
2010; Oehen et al., 2013) and in subjects with no or minimal prior ecstasy use, which is also 
likely the case when MDMA is used in patients. The aims of the study were to describe 
subjective effects (self-rated good and bad drug effects), the duration of the acute MDMA 
response, cardiovascular and hyperthermic effects, and acute and subacute adverse effects, 
and lasting effects on laboratory indices of liver and kidney function. We also tested the 
moderating effects of dose (Kolbrich et al., 2008a; Schmid et al., 2014; de la Torre et al., 
2000) and sex (Liechti et al., 2001; Verheyden et al., 2002; Simmler et al., 2011; Pardo-
Lozano et al., 2012; Reneman et al., 2001) on these acute responses to MDMA. 
The pharmacology of MDMA has been relatively well-studied. MDMA mainly 
induces the release of presynaptic serotonin (5-hydroxytryptamine [5-HT]) and to a lesser 
extent norepinephrine (NE) and dopamine (DA) through interactions with the corresponding 
monoamine transporters (Simmler et al., 2013; Hysek et al., 2012d; Rothman et al., 2001). 
MDMA is generally classified as an “entactogen” or “empathogen” because its socio-
emotional effects differ from those of prototypic stimulants (Bershad et al., 2016; Hysek et 
al., 2014b; Schmid et al., 2014), and it produces fewer perceptual alterations than 
hallucinogens (Schmid et al., 2015a). Specifically, MDMA increases feelings of closeness to 
others, trust, and openness and enhances emotional empathy for positive situations (Hysek et 
al., 2014a; Schmid et al., 2014). Such effects are not observed with stimulants that 
predominantly act on the DA system (Schmid et al., 2014). MDMA (Baggott et al., 2016) but 
not D-amphetamine (Childs et al., 2016) decreased social anxiety. MDMA selectively 
impaired the recognition of negative emotions (Hysek et al., 2014a; Schmid et al., 2014; Bedi 
et al., 2010; Wardle et al., 2014), whereas such stimulants as amphetamine and 
methylphenidate nonselectively enhanced the recognition of emotions (Hysek et al., 2014b; 
Schmid et al., 2014; Wardle et al., 2012). These findings indicate that MDMA produces 
unique effects on emotion processing in healthy subjects that are likely linked to its 
predominant effects on the 5-HT system (Bershad et al., 2016; Hysek et al., 2012d; Hysek et 
al., 2012b) and may be useful in MDMA-assisted psychotherapy (Sessa, 2016).  
Earlier studies that described the acute effects of MDMA in healthy volunteers have 
previously been reviewed (Dumont and Verkes, 2006), but many more have been performed 
since then (Dumont et al., 2009; Dumont et al., 2008; Kuypers et al., 2014; de Sousa 
Fernandes Perna et al., 2014; van Wel et al., 2012; Schmid et al., 2015b; Hysek et al., 2014b; 
Schmid et al., 2014; Hysek et al., 2013; Hysek et al., 2012d; Hysek et al., 2012a; Hysek et al., 
2012c; Hysek et al., 2011; Farre et al., 2015; Peiro et al., 2013; Pardo-Lozano et al., 2012; 
Farre et al., 2007; Kolbrich et al., 2008a; Hasler et al., 2009; Carhart-Harris et al., 2014; 
Kirkpatrick et al., 2014b; Kirkpatrick et al., 2014a; Kirkpatrick et al., 2012; Parrott et al., 
2011). However, all of these individual studies were relatively small (N = 6-30) in particular 
to characterize adverse events that are not very common (< 10%), and safety aspects were not 
the primary endpoint or were not described. Additionally, we are unaware of any larger data 
analyses (N > 100) that focused on the clinical safety profile of acute MDMA administration. 
The present analyses used a relatively large sample size including data from 166 subjects 
(equal numbers of males and females) and 166 administrations of MDMA alone and 112 
administrations of MDMA with another substance. In contrast to compilations of data form 
different laboratories, the present data set used the same doses and formulations of MDMA 
and the same standardized outcome measures across all the individual studies including 
measures of plasma levels of MDMA. We hypothesized that MDMA would produce 
predominantly positive mood effects (Hysek et al., 2014a; Kolbrich et al., 2008a; Baggott et 
al., 2016) and cardiostimulant (Schmid et al., 2016) and thermogenic (Liechti, 2014) 
responses. Renal failure and hepatotoxicity are potential consequences of uncontrolled 
ecstasy use (Liechti et al., 2005; Ben-Abraham et al., 2003), but we did not expect to see 





 This was a pooled analysis of nine Phase I double-blind, placebo-controlled, crossover 
studies in healthy subjects (Hysek et al., 2012a; Hysek et al., 2012c; Hysek et al., 2012d; 
Hysek et al., 2011; Hysek and Liechti, 2012; Hysek et al., 2014b; Schmid et al., 2014; 
Schmid et al., 2015b). These studies were all conducted at the University Hospital Basel and 
included a total of 166 subjects who were all psychiatrically screened and healthy. The aim of 
the pooled analysis was to assess the safety pharmacology of one or two single doses of 
MDMA in healthy subjects with no regular MDMA use and no or minimal previous use. 
Seven studies each included 16 subjects (total of 112 subjects) who received 125 mg MDMA 
twice, once alone and once after pretreatment with a medication (Hysek et al., 2012a; Hysek 
et al., 2012c; Hysek et al., 2012d; Hysek et al., 2011; Hysek and Liechti, 2012; Hysek et al., 
2014b; Schmid et al., 2015b). An additional unpublished study included 24 subjects who 
received 125 mg MDMA once without pretreatment (ClinTrials.gov ID: NCT01951508). 
Lastly, one study included 30 subjects who received a single dose of 75 mg MDMA without 
pretreatment (Schmid et al., 2014). The focus of this analysis is on the acute effects of 
MDMA alone. Effects of MDMA with pretreatments are shown in the supplementary 
material. In all of the studies, the washout periods between the MDMA single-dose 
administrations were at least 7 days to exclude carry-over effects. The studies were all 
registered at ClinicalTrials.gov (NCT00886886, NCT00990067, NCT01136278, 
NCT01270672, NCT01386177, NCT01465685, NCT01771874, NCT01951508, and 
NCT01616407). All of the studies were approved by the local ethics committee and Swiss 
Agency for Therapeutic Products (Swissmedic). The studies were conducted in accordance 
with the Declaration of Helsinki. MDMA administration in healthy subjects was authorized 
by the Swiss Federal Office for Public Health (BAG), Bern, Switzerland. Informed consent 
was obtained from all of the participants who were included in the studies. All of the subjects 
were paid for their participation. 
 
Subjects 
 A total of 166 healthy European/Caucasian subjects, aged 18-45 years (mean ± SD = 
24.5 ± 4 years) were mostly recruited from the University of Basel campus and included in 
the studies. The mean ± SD body weight was 69 ± 10 kg (range: 46-95 kg). Thirty subjects 
(15 men, 15 women) received a single 75 mg dose of MDMA. One hundred thirty-six 
subjects received a single 125 mg dose of MDMA. In these 136 subjects, MDMA was 
administered as a single dose in 24 subjects (12 men, 12 women) and as two single doses of 
125 mg (once alone and once combined with another drug on two separate occasions at least 
7 days apart) in 112 subjects (56 men, 56 women), resulting in total exposure of 250 mg 
MDMA. The time interval between the two MDMA administrations was 26 ± 17 days. 
The detailed exclusion criteria were reported elsewhere (Hysek et al., 2012a; Hysek et 
al., 2012c; Hysek et al., 2012d; Hysek and Liechti, 2012), including a history of psychiatric 
disorders, physical illness, a lifetime history of using illicit drugs more than five times (with 
the exception of past cannabis use), illicit drug use within the last 2 months, and illicit drug 
use during the study, determined by urine tests that were conducted before the test sessions. 
Fifty-nine subjects had prior drug experience (1-5 times), of which 34 subjects had previously 
used MDMA (1-4 times). 
 
Study drug 
 (±)MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) was administered 
orally in a single dose of 75 or 125 mg prepared as gelatin capsules (25 or 100 mg, Bichsel 
Laboratories, Interlaken, Switzerland). Similar amounts of MDMA are found in ecstasy pills 
(Brunt et al., 2012) and have been or are being used in clinical studies in patients (Oehen et 
al., 2013; Mithoefer et al., 2010). Male and female subjects were treated with the same 125 
mg dose irrespective of body weight in the clinical studies in patients (Oehen et al., 2013; 
Mithoefer et al., 2010). Similarly, in the present study, the doses were not adjusted for body 
weight or sex. The dose per body weight (mean ± SD) was 1.7 ± 0.4 mg/kg (range: 0.8-2.7 
mg/kg). For the 75 mg dose of MDMA, the dose per body weight was 1.0 ± 0.1 mg/kg for 
men and 1.2 ± 0.1 mg/kg for women. For the 125 mg dose of MDMA, the dose per body 
weight was 1.7 ± 0.2 mg/kg for men and 2.1 ± 0.3 mg/kg for women. 
 
Pharmacodynamic measures 
 Visual Analog Scales (VASs) were repeatedly used to assess subjective effects over 
time (Hysek et al., 2014a). The VASs included “any drug effect,” “good drug effect,” and 
“bad drug effect.” The VASs were presented as 100-mm horizontal lines (0-100%), marked 
from “not at all” on the left to “extremely” on the right. The VASs were applied before and 0, 
0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. In the study 
that evaluated 75 mg MDMA, the 0.33 h time point is missing. In one study that evaluated 
125 mg MDMA (N = 24), the 2 and 2.5 h time points are missing. The onset, offset, and 
duration of the subjective response were determined using the VAS “any drug effect”-time 
curve, with 10% of the individual maximal response as the threshold, in Phoenix WinNonlin 
(Version 6.4, Pharsight, Certara L.P., St. Louis, MO, USA). Because subjective effects were 
assessed only up to 6 h, the offset in two subjects with an effect > 10% at 6 h was determined 
by log-extrapolation. Four subjects were excluded from this analysis because they reported 
no subjective effects. 
Blood pressure, heart rate, and body temperature were assessed repeatedly before and 
0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, and 6 h after MDMA or placebo administration. Systolic 
and diastolic blood pressure and heart rate were measured using an automatic oscillometric 
device (OMRON Healthcare Europe NA, Hoofddorp, Netherlands). The measurements were 
performed in duplicate at an interval of 1 min and after a resting time of at least 10 min. The 
averages were calculated for analysis. Core (tympanic) temperature was measured using a 
Genius
TM
 2 ear thermometer (Tyco Healthcare Group LP, Watertown, NY, USA). In the 
study that evaluated 75 mg MDMA, the 0.33 h and 2.5 h time points are missing. In one 
study that evaluated 125 mg MDMA (N = 24), the 2 h time point is missing. Criteria for 
grouping subjects at least > 90, 100, and 110 mmHg for diastolic and > 140, 160 and 180 
mmHg for systolic hypertension grade I-III, respectively. Tachycardia was defined as > 100 
beats/min. Hyperthermia and hyperpyrexia were defined as tympanic body temperature > 38 
and 40 °C, respectively.  
 
Acute and subacute adverse effects were assessed using the list of complaints (LC; 
(Zerssen, 1976; Hysek et al., 2012a). The scale consisted of 66 items, yielding a total adverse 
effects score (non-weighted sum of the item answers) that reliably measures physical and 
general discomfort. Bruxism (item 66, a common side effect of MDMA) was included in the 
LC that was used in 134 subjects. The LC was administered before and 3-6 (acute adverse 
effects up to 6 h) and 24 h (subacute adverse effects up to 24 h) after MDMA or placebo 
administration. Additionally, participants were asked at the beginning of each study session 
and at the end of study visit to report any adverse events for the periods from 24 h until 14 
days after administration.  
 
Plasma concentrations of MDMA 
Blood samples were collected 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, and 6 h after administration of 
MDMA or placebo. Plasma concentrations of MDMA were determined as previously 
described (Hysek et al., 2012d). Peak plasma concentrations (Cmax) were obtained directly 
from the observed data. The area under the concentration-time curve (AUC) from 0 to 6 h 
after dosing (AUC6) was calculated using the linear-log trapezoidal method in Phoenix 
WinNonlin 6.4 (Certara, Princeton, NJ, USA). 
 Blood sampling and end of study visit 
 Blood chemistry and blood cell count tests were performed at the screening visit at the 
start of the study and at the end of study (EOS) visit, which were separated by 88 ± 50 days. 
The EOS including the blood sampling took place at variable time intervals (29 ± 22 days) 
after the last MDMA administration and after one or two administrations of MDMA with or 
without pretreatments. The analyses were performed using standard assays according to Good 
Laboratory Practice by the Laboratory Medicine Department of the hospital. The glomerular 
filtration rate was determined by the Cockcroft-Gault Equation using plasma creatinine 
concentrations, age, and sex of the subject. At the EOS visit, the participants were asked to 
retrospectively rate the duration of the subjective response to MDMA, whether the 
experience was positive or negative, whether the controlled clinical setting influenced their 
experience, and whether they considered taking MDMA again and in what setting. The 
participants were also asked whether they experienced “flashbacks.” These questions were 
asked in 141 subjects. 
 
Statistical analyses 
 The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, 
OK, USA). Repeated-measures analyses of variance (ANOVAs) with drug (MDMA alone 
without pretreatment vs. placebo) as the within-subjects factor and dose (75 vs. 125 mg) as 
the between-subjects factor were used to evaluate all the effects of MDMA compared with 
placebo (main effect of drug) and dose-response effects (drug × dose interactions). Sex 
differences were explored by adding sex as an additional between-subjects factor to the 
analyses. Tukey post hoc test were used based on significant main effects or interactions in 
the ANOVA. Finally, dose per body weight and peak plasma concentrations of MDMA were 
used as a covariate to test whether sex differences were confounded by dose per body weight 
or plasma concentrations of MDMA, respectively. The latter analysis also accounted for 
potential differences in metabolism and non-linear pharmacokinetics. Fisher’s exact tests 
were used to compare proportions. Differences in kidney and liver function and blood cell 
counts between the screening and EOS visit measures were analyzed using paired t-tests. The 
level of significance was set to p < 0.05. 
 
Results 
Acute subjective effects of MDMA 
 The time course of the subjective response to MDMA alone is shown in Fig. 1. The 
onset of effects and peak effect were 33 ± 24 min (mean ± SD) and 1.6 ± 0.8 h after MDMA 
administration, respectively. The duration of the subjective drug effects was 4.2 ± 1.3 h 
(range: 1.4-8.2 h). No sex or dose differences were found in the duration of the subjective 
effects. At the EOS visit, the subjects retrospectively indicated that the duration of their 
subjective response to MDMA was 4.0 ± 2.9 h. MDMA significantly increased ratings of 
“any drug effect” and “good drug effect” compared with placebo (Table 1, Fig. 1). The 125 
mg dose of MDMA produced higher “any drug effect” and “good drug effect” ratings 
compared with the 75 mg dose of MDMA (Table 1, Fig. 1). A nearly significant drug × sex 
interaction in the ANOVA indicated that women tended to give greater “any drug effect” 
ratings than men (Table 1, Fig. 1). MDMA increased ratings of “bad drug effect.”  “Bad drug 
effect” ratings were not dose-dependent in contrast to “good drug effect” ratings. “Bad drug 
effect” ratings were greater in women than in men. When we accounted for the higher mg/kg 
dose in women by adding it as a covariate in the analysis, women still gave significantly 
greater “bad drug effect” ratings than men after MDMA administration compared to placebo 
(F1,162 = 20.0, p < 0.001). The sex difference also remained significant after correcting for 
differences in peak plasma concentrations of MDMA (F1,162 = 21.5, p < 0.001).    
 
Acute effects of MDMA on vital signs 
 MDMA alone acutely increased blood pressure, heart rate, and body temperature 
(Table 2). A significant dose-response effect of MDMA on blood pressure but not heart rate 
or body temperature was found (Table 2). The acute effect of MDMA on systolic blood 
pressure, heart rate, and body temperature peaked after 1.7 ± 0.9 h, 2.0 ± 1.4 h, and 2.4 ± 1.2 
h, respectively. No sex differences in the effects of MDMA on vital signs were observed. 
However, when we accounted for the lower mg/kg dose in males compared with females by 
adding it to the analysis (i.e., dose normalization), men presented greater increases in systolic 
blood pressure compared with women (F1,164 = 6.08, p < 0.05). Blood pressure increases were 
also greater in men than women when correcting for plasma concentrations of MDMA (F1,164 
= 8.28, p < 0.01). After MDMA administration, 54 subjects (33%) and seven subjects (4%) 
had systolic blood pressure > 160 and 180 mmHg, respectively. The proportion of subjects 
with systolic blood pressure > 160 mmHg was significantly greater after 125 mg MDMA 
administration compared with 75 mg (p < 0.01). Forty-eight subjects (29%) presented 
tachycardia (heart rate > 100 beats/min). The proportion of subjects with heart rate > 100 
beats/min was significantly greater after 125 mg MDMA administration compared with 75 
mg (p < 0.05). MDMA increased body temperature to > 38 °C in 32 subjects (19%), up to a 
maximum of 39.1 °C. The proportion of subjects with body temperature > 38 °C was 
significantly greater after 125 mg MDMA administration compared with 75 mg (p < 0.01). 
The mean room temperature was 22.7 ± 0.6 °C. The effects of co-administering MDMA with 
other medications on vital signs are shown in Supplementary Table S1. No hypertensive 
urgencies or incidents of hyperpyrexia (> 40 °C) occurred. The maximal diastolic and 
systolic blood pressure values among the 166 administrations of MDMA alone were 130 and 
196 mmHg, respectively. The maximal diastolic and systolic blood pressure values among 
the 112 administrations of MDMA plus a pretreatment were 119 and 200 mmHg, 
respectively. The maximal observed body temperature value among all 278 administrations 
of MDMA alone or with pretreatment was 39.1 °C.  
 
Adverse effects of MDMA 
 MDMA produced significant acute and subacute adverse effects on the LC compared 
with placebo (Table 1 and 2). The 125 mg dose of MDMA increased acute and subacute LC 
total scores significantly more than the 75 mg dose (Table 2). MDMA increased acute LC 
ratings more in women (8.8 ± 5.9) than in men (6.4 ± 6.8; Table 1). MDMA also increased 
subacute LC scores more in women (5.4 ± 5.5) than in men (3.0 ± 5.0; Table 1). The 
difference in the acute and subacute adverse effects between women and men remained 
significant after correcting for differences in the mg/kg dose of MDMA (F1,162 = 6.27, p < 
0.05, and F1,162 = 6.21, p < 0.05, respectively) or differences in the plasma concentration of 
MDMA (F1,162 = 6.13, p < 0.05, and F1,162 = 4.63, p < 0.05, respectively). 
Frequent and relevant complaints after MDMA and placebo administration are shown 
in Table 3. The most frequent acute adverse effects after MDMA administration included 
lack of appetite, dry mouth, difficulty concentrating, cold feet, sweating, bruxism, restless 
legs, dizziness, and hot flushes. Significant subacute (24 h) adverse effects of MDMA 
included headache, lack of appetite, lack of energy, dry mouth, difficulty concentrating, and 
bruxism. Acute dry mouth, difficulty concentrating, sweating, and bruxism were more 
frequently observed after 125 mg MDMA compared with 75 mg. Acute anxiety was reported 
by nine subjects (6%) after the 125 mg dose and none of the subjects after the 75 mg dose 
(Supplementary Table S2). No serious adverse events were reported. Additional adverse 
events that were reported for the periods from 24 h until 7-14 days after drug administration 
included the following (0% if not mentioned): headache, 6% after 125 mg MDMA, 7% after 
75 mg MDMA, and 5% after placebo; depressed mood, 4% after 125 mg MDMA; common 
cold: 2% after 125 mg MDMA, 4% after placebo; dysmenorrhea: 10% after 75 mg MDMA; 
diarrhea: 2% after 125 mg MDMA; dizziness: 2% after 125 mg MDMA; gastroenteritis: 3% 
after 75 mg MDMA, 1% after placebo; emesis: 2% after 125 mg MDMA; toothache: 2% 
after 125 mg MDMA; jaw muscle soreness: 1% after 125 mg MDMA; migraine: 1% after 
125 mg MDMA; back pain: 1% after 125 mg MDMA; sinusitis: 1% after 125 mg MDMA; 
abdominal pain: 1% after 125 mg MDMA, 1% after placebo; flu: 1% after 125 mg MDMA; 
bronchitis: 3% after 75 mg MDMA. These adverse events were not reported significantly 
more frequently after MDMA administration compared with placebo. There were several 
adverse events that occurred only after placebo: sleep walking, herpes zoster, insomnia, 
syncope, upper ankle joint distortion, pneumonia, nausea, inflamed mosquito bites, infection 
of the eye, dry cough, and abscess in the inguinal region combined with tinea of the body 
(each in 1% of the subjects). In the studies that used 125 mg MDMA, a total of 12 subjects 
(9%) reported flashbacks 1-3 times and 8 times in one subject. Flashbacks reportedly 
occurred 26 ± 15 h after MDMA administration (range: 8-50 h). No sex differences were 
found in the reports of adverse events or flashbacks. 
 
Plasma concentrations of MDMA 
Plasma concentrations of MDMA for both doses and sexes are shown in Table 1. Peak 
plasma concentrations of MDMA were significantly and on average 1.8-fold higher after the 
125 mg dose (224.1 ng/ml) compared to the 75 mg dose (124.5 ng/ml). Statistical comparison 
of the dose-normalized Cmax values revealed a significant difference in the total sample (F1,161 
= 4.19, p < 0.05) which was significant only in women (p < 0.05), indicating nonlinear 
pharmacokinetics, but not in men (p = 1.0). Peak concentrations were on average 1.9- and 
1.7-fold higher after the 125 mg compared with the 75 mg dose in women and men, 
respectively. At the same 125 mg dose, women showed on average 1.29- and 1.26-fold higher 
Cmax and AUC6 levels compared with men, respectively.  
   
Effects of MDMA on kidney and liver function and changes in blood cell counts 
 At the end of the study and 30 ± 22 days after the last of one or two administrations of 
MDMA plus pretreatments in some of the studies, plasma creatinine levels and the estimated 
glomerular filtration rate were unchanged compared with the start of the study and before 
MDMA administration (Table 4). Similarly, plasma levels of aspartate aminotransferase, 
alanine aminotransferase, and γ-glutamyl transpeptidase were similar at the screening and at 
the EOS visits. Red blood cell counts and hemoglobin levels decreased, and thrombocyte 
levels increased during the study. White blood cell counts remained unchanged. Red blood 
cells and hemoglobin were reduced significantly more in women than in men (F1,159 = 8.12, p 
< 0.01, and F1,159 = 12.9, p < 0.001). The decrease did not reach statistical significance in 
men. 
 
Subjects’ interest in using MDMA again 
 Eighty percent of the subjects were MDMA-naive, and the rest had very limited 
experience with MDMA (i.e., ≤ 4 exposures at most). One hundred forty-one subjects were 
asked whether they would consider taking MDMA again. Twenty-seven subjects (19%) 
reported that they would probably not take MDMA again under any circumstances. Sixty-six 
subjects (47%) reported that they would not use MDMA in a recreational setting but might 
consider participating in another study with MDMA administration under controlled 
conditions. Forty-eight subjects (34%) indicated that they may consider taking MDMA in a 
recreational setting but only if the identity, purity, and dose were known. Twenty-four of 
these 48 subjects (50%) had taken illicit drugs previously, including MDMA. Only 13 
subjects considered taking MDMA in a club setting. Ninety-five subjects (67%) reported a 
positive overall MDMA experience, 25 subjects (18%) reported a neutral experience, and 21 
subjects (15%) reported a disappointing or bad experience. No sex differences were observed. 
Fifty-one subjects (36%) reported that the controlled setting had no impact on their 
experience, whereas 90 subjects (64%) reported that the controlled setting was important for 
their type of experience and was reassuring and made them feel safe. Women rated the setting 
as significantly more important than men (F1,139 = 12.4, p < 0.001). 
 
Discussion 
 The present study analyzed pooled data from nine placebo-controlled Phase I studies 
and characterized the acute effects of MDMA in healthy subjects, with a focus on tolerability 
and clinical safety. The safety considerations included aspects of psychological and physical 
harm. The present study showed clearly greater positive than negative acute subjective 
effects. MDMA induced a state of predominantly positive mood across different laboratories 
(Kolbrich et al., 2008a; Baggott et al., 2016; Hysek et al., 2014a; Tancer and Johanson, 2003; 
Dumont and Verkes, 2006; Kirkpatrick et al., 2014a; Kamilar-Britt and Bedi, 2015; Bershad 
et al., 2016; Kuypers et al., 2014; Farre et al., 2007; Kirkpatrick et al., 2012), with one 
exception (Parrott et al., 2011). Modest apprehension anxiety was present in some subjects as 
previously reported (Dumont and Verkes, 2006; Liechti et al., 2001), whereas social anxiety 
has been shown to decrease (Baggott et al., 2016). In the present study, anxiety was reported 
in the LC as an acute adverse effect by 7% of the subjects after 125 mg MDMA 
administration but not after 75 mg. In our experiments, anxiety could be reduced by verbal 
support in all of the subjects, and benzodiazepines were not used. There were no cases of 
severe anxiety or panic attacks. Psychological distress was minimal. Overall positive 
subjective experiences were retrospectively reported in two-thirds of the participants in the 
present study, whereas 15% of the subjects were rather disappointed by the effects of MDMA 
or had bad experiences. In contrast to the findings from the present controlled studies, panic 
attacks and agitation/aggression are common psychiatric complications in recreational 
ecstasy users who present to emergency departments (Liechti et al., 2005; Wood et al., 2016; 
Halpern et al., 2011).  
The present study also determined the exact time course of the overall subjective 
response to MDMA. The average onset time, peak time, and effect duration (33 min, 1.6 h, 
and 4.2 h, respectively) were comparable to previous studies (Liechti et al., 2001; Hysek and 
Liechti, 2012; Kolbrich et al., 2008a; Farre et al., 2004; Mithoefer et al., 2010). The effect 
duration represented the time an individual experienced a subjective drug effect ≥ 10% of 
his/her own peak response. It has been suggested that the duration of the effect of MDMA 
(125 mg) could be prolonged by another dose (62.5 mg) 2 h after the initial dose (Sessa, 
2016; Mithoefer et al., 2010). However, the short duration of action of MDMA relative to its 
long plasma half-life (Kolbrich et al., 2008b; Hysek et al., 2011) is attributable to acute 
pharmacological tolerance. Thus, the subjective effects decline despite high concentrations of 
MDMA in the body (Hysek et al., 2012a; Hysek et al., 2011). Therefore, adding more 
MDMA to increase the MDMA concentration in the body might not relevantly prolong the 
limited effect duration and may increase adverse effects (Peiro et al., 2013). In line with this 
view, the effect duration of the 75 and 125 mg dose of MDMA did not differ in the present 
study. In contrast to MDMA, acute pharmacological tolerance was not observed with lysergic 
acid diethylamide (LSD), which is also investigated in substance-assisted psychotherapy 
(Gasser et al., 2014) and the effect duration of LSD was shown to be dose-dependent (Dolder 
et al., 2015; Dolder et al., 2016).  
In terms of potential physical harm, MDMA induced sympathomimetic activation. 
MDMA produced at least moderate hypertension (systolic blood pressure > 160 mmHg) and 
tachycardia (heart rate > 100 beats/min) in one-third of the participants. Thus, although the 
participants were resting, they presented changes in vital signs that were similar to moderate 
physical activity. Transient severe hypertension (systolic blood pressure > 180 mmHg) was 
observed in 5% of the participants who received 125 mg MDMA. Severe hypertension may 
lead to complications including stroke and heart attacks in vulnerable persons. No other signs 
or symptoms of hypertensive crises (severe headache, shortness of breath, or nosebleeds) 
were observed in the present study. Similarly, a previous analysis that included 74 subjects 
from laboratory studies found systolic blood pressure ≥ 160 and ≥ 180 mmHg in 32% and 9% 
of the subjects, respectively (Liechti et al., 2001). Other stimulant drugs, such as 
methamphetamine, D-amphetamine, and methylphenidate, produced comparable 
cardiovascular stimulation to MDMA when administered as single oral doses (Hysek et al., 
2014b; Schmid et al., 2014; Bershad et al., 2015; Martin et al., 1971; Wardle and De Wit, 
2012; Brauer et al., 1996; Kirkpatrick et al., 2012).  
The present study also found statistically significant MDMA-induced increases in body 
temperature, but body temperatures did not increase to > 39.1 °C, consistent with previous 
studies (Freedman et al., 2005; Liechti, 2014; Kolbrich et al., 2008a). There can be 
considerable variance in the thermal reactions to acute MDMA (Liechti, 2014; Kolbrich et 
al., 2008a). Hyperpyrexia (> 40 °C) is rare but represents the most important life-threatening 
complication of recreational MDMA use (Wood et al., 2016; Liechti et al., 2005; Liechti, 
2014; Grunau et al., 2010; Halpern et al., 2011; Henry et al., 1992). No controlled clinical 
study of MDMA has reported MDMA-induced hyperpyrexia, possibly because the 
participants were treated with moderate single doses at rest, were well-hydrated, and were not 
in a hot or crowed environment, unlike in some recreational settings that are known to 
increase the risk of hyperpyrexia (Dafters, 1995). 
In the present study, the participants reported a series of MDMA-induced acute and 
subacute adverse effects. These effects were consistent with moderate sympathomimetic 
toxicity, including lack of appetite, dry mouth, cold feet, sweating, restlessness, and heart 
palpitation. The most frequently reported adverse effects 24 h after MDMA administration 
were headache, lack of energy, and lack of appetite. Depressed mood, including emotional 
irritability, lack of energy, brooding, and bad dreams, has previously been reported in up to 
one-third of subjects, lasting up to 3 days in some subjects (Liechti et al., 2001). Anxiety, 
difficulty concentrating, irritability, and loss of appetite were also noted in the week 
following MDMA use in psychotherapy (Mithoefer et al., 2010; Oehen et al., 2013). 
Similarly, ecstasy users reported mid-week depression following weekend MDMA use 
(Verheyden et al., 2002). 
Hallucinogen persisting perception disorder has been described following recreational 
ecstasy use (Litjens et al., 2014). One hundred forty-one participants in the present study 
were asked at the end of the study whether they experienced flashbacks. Twelve subjects 
(9%) reported flashbacks, but only within 8-50 h after drug administration. Thus, our study 
found no evidence of persisting perceptual alterations after MDMA administration in a 
controlled setting. 
In the present study, MDMA did not influence levels of liver enzymes on average 1 
month after administration. Although direct hepatotoxic effects of MDMA are unlikely at the 
doses used, there is evidence of rare idiosyncratic hepatotoxicity (Henry et al., 1992; Ellis et 
al., 1996; Atayan et al., 2015; Maharaj et al., 2015). This type of hepatotoxicity is observed 
with many marketed medications. The decrease in red blood cells and increase in 
thrombocytes that were observed over the time course of the present study were attributable 
to the sampling of blood (400-600 ml) for pharmacokinetic analyses and not a consequence 
of MDMA use. 
Although the 125 mg dose of MDMA was 1.67-fold higher than the 75 mg dose, it 
produced 1.8-fold higher Cmax and AUC6 values than the 75 mg dose, indicating nonlinear 
dose-exposure relationship. This finding is in line with previous studies (Kolbrich et al., 
2008a; Schmid et al., 2014; de la Torre et al., 2000) but statistically significant only in 
women and not in men at the doses tested in the present study. At the same fixed 125 mg 
dose of MDMA, women showed 1.29-fold higher Cmax levels than men, which could be 
explained mainly by their 1.24-fold lower body weight.In the present study, subjective “bad 
drug effect” ratings and other adverse acute and after-effects were greater in women than in 
men. These negative effects of MDMA were significantly greater in women than men even 
when correcting for the higher dose per body weight or significantly higher plasma levels in 
women compared with men. Similarly, greater acute and subacute adverse effects were 
previously reported in women compared with men in an analysis of studies that used body 
weight-adjusted dosing of MDMA (Liechti et al., 2001). Previous studies also found greater 
MDMA-induced negative subjective effects, including “fear of loss of body control” and 
“thought disorders” (Liechti et al., 2001), as well as dizziness and sedation (Pardo-Lozano et 
al., 2012) in women than in men. Higher mid-week depression scores in women than in men 
following weekend MDMA use have also been reported (Verheyden et al., 2002). Women 
may be more susceptible to the adverse effects of MDMA on the serotonin system (Reneman 
et al., 2001). Men presented higher acute blood pressure responses than women (Liechti et 
al., 2001), consistent with the greater cardiovascular stimulant effects of MDMA in men than 
in women, after dose-normalization in the present study. In contrast, women presented higher 
heart rates than men in another smaller study (Pardo-Lozano et al., 2012). To our knowledge, 
no other laboratory studies have specifically reported sex differences in the acute subjective 
and physiological effects of MDMA. The present findings may be useful for dose selection in 
MDMA-assisted psychotherapy in patients with PTSD. Women had similar adverse effects 
scores on the LC after 75 mg MDMA administration compared with men that received 125 
mg, suggesting that the lower dose should be used in female patients. However, significantly 
higher subjective “good drug effect” ratings and comparable “bad drug effect” ratings were 
reported in women after 125 mg MDMA administration compared with 75 mg. Based on our 
data, we suggest that a fixed dose of 100 mg may be a good choice in women and comparable 
to the 125 mg dose in men. This dose adjustment would also account for the approximately 
1.3 times higher plasma peak levels of MDMA in women compared with men at the 125 mg 
dose shown in the present study. Doses up to 187.5 mg have been safely used in mostly 
women in MDMA-assisted psychotherapy (Mithoefer et al., 2010; Oehen et al., 2013). 
Whether these high doses are indeed needed in female patients to achieve therapeutic effects 
requires further study. 
The present safety data can in part be applied to the use of MDMA in patients. In 
patients, MDMA is typically used sporadically 2-3 times and spaced several weeks apart 
along in addition to non-substance assisted psychotherapy (Sessa, 2016; Oehen et al., 2013; 
Mithoefer et al., 2010). The same 125 mg dose of MDMA was used in the present study and 
in MDMA-assisted psychotherapy (Oehen et al., 2013; Mithoefer et al., 2010). The study 
participants typically had no or very little previous MDMA experience, similar to patients. In 
the research setting that is used in our laboratory, a research assistant is always present with 
the participants, similar to a therapy session (Oehen et al., 2013; Mithoefer et al., 2010), in 
contrast to some other experimental settings (Kirkpatrick et al., 2014a). However, the 
subjective response to MDMA may be different in patients with psychiatric disorders 
compared with subjects who are screened to be psychiatrically healthy. Consistent with the 
present data, there have been no reports to date of serious adverse reactions in clinical 
MDMA studies (Doblin et al., 2014; Oehen et al., 2013; Mithoefer et al., 2010). 
The present study has limitations. We included only psychiatrically healthy subjects and the 
risks of using MDMA in persons with psychiatric disorders may be different (Greer and 
Tolbert, 1986; Vollenweider et al., 1998; Parrott, 2007) and also need to be investigated. For 
example, the use of MDMA has been reported to acutely induce negative moods and 
cognitions, and other undesirable psychological effects in psychotherapy, (Greer and Tolbert, 
1986; Parrott, 2007). We included mostly young subjects, but older patients with mainly 
more cardiovascular risk factors may also be treated in MDMA-assisted psychotherapy. 
Hyponatremia is frequently observed in ecstasy intoxications (Halpern et al., 2011; Rosenson 
et al., 2007; Hartung et al., 2002) but was not assessed in the present study. Additionally, we 
did not evaluate neurocognitive function or any other correlates of neurotoxicity or long-term 
problems (Parrott, 2013b; Rogers et al., 2009; Mueller et al., 2016; Parrott, 2014; Kuypers et 
al., 2016). Laboratory markers of liver and renal function were only assessed at the end of the 
study and on average one month after the last MDMA administration not excluding short-
lasting transient changes in these parameters. Finally, the sample size of the present pooled 
analysis of 166 administrations of MDMA alone or 278 administrations of MDMA alone or 
with a pretreatment was too small to exclude infrequent (0.1-1%) or rare (< 0.1%) adverse 
events. For example, we observed no event of hyperpyrexia among the 278 MDMA 
administrations and the 95% confidence interval for no event among 278 observations 
calculated using the binomial distribution is 0-1.3%.  
Conclusion 
 Single-dose administration of MDMA was safe in healthy subjects and in a controlled 
clinical setting. Acute subjective effects were predominantly positive. Subjective adverse 
effects were more frequently reported in women that in men. A fixed dose of 100 mg is likely 
more appropriate for women and comparable to the 125 mg dose in men. These safety data 
do not raise any concerns related to further studies of MDMA as an adjunct to psychotherapy 
in controlled medical environments. However, MDMA dose-dependently induced 
cardiovascular stimulation, which may be greater in men and should be considered a 
significant risk for patients with cardiovascular disease. Finally, the risks and benefits of 
using MDMA in patients with psychiatric disorders need further study.  
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Figure and Tables Legends 
 
Figure 1. Subjective effects of MDMA. (a) The overall subjective effect (“any drug effect”) 
began after a mean time of 33 min, reached its peak after 1.6 h, and lasted 4.2 h (effect 
duration from onset to offset with a threshold of 10% of the peak). (a, b) MDMA produced 
greater “any drug effect” and “good drug effect” ratings at 125 mg compared with 75 mg. (c) 
MDMA produced moderate and transient “bad drug effect” ratings that were not dose-
dependent but greater in women than in men. The data are expressed as the mean ± SEM in 
15 women and 15 men for the 75 mg dose and 68 women and 68 men for the 125 mg dose.  
Table 1. Subjective effects and adverse effects in men and women
Emax (mean±SD) Placebo MDMA Placebo MDMA Placebo MDMA Placebo MDMA F1,162 P = F1,162 P = F1,162 P = F1,162 P =
any drug effect 3±6 59±29*** 4±8 85±20***### 6±9 56±32*** 4±13 73±24***# 652 <0.001 20 <0.001 3.4 0.068 0.2 NS
good drug effect 6±13 60±28*** 3±10 82±25***## 7±12 57±33*** 4±15 77±23***## 585 <0.001 20 <0.01 0.9 NS 0.04 NS
bad drug effect 4±13 35±33*** 2±10 24±24*** 6±16 7±11+++ 2±10 13±21***+ 44 <0.001 0.001 NS 16 <0.001 3.6 0.059
List of Complaints score (mean±SD)
before, N 1.5±1.6 2.1±2.5 1.6±2.0 1.6±1.8 0.7±1.4 0.7±1.3 1.4±2.4 1.2±1.8 0.1 NS 0.7 NS 0.5 NS 0.2 NS
acute, up to 6h, N 2.2±2.2 8.2±4.6** 2.2±2.3 11.6±6.1*** 1±1.7 3±2.4+ 1.1±2.1 8.5±6.9***##++ 99 <0.001 12 <0.001 5.9 <0.05 0.6 NS
subacute, up to 24h, N 0.9±1.5 4.1±5.2 1.2±2.1 7.1±5.7*** 1±1.6 1.6±2.4 0.6±2.3 4.2±5.1***+++ 41 <0.001 7.3 <0.01 5.8 <0.05 0.02 NS
N: number of subjects; SD: standard deviation; **P < 0.01, ***P < 0.001 compared to placebo, #P < 0.05, ##P < 0.01, ###P < 0.001 compared to 75mg; +P < 0.05, ++P < 0.01, +++P < 0.001 compared to women; NS: not significant
women men




Table 2. Maximal effects on vital signs and adverse effects
Placebo MDMA Placebo MDMA
MDMA dose F1,165 P = F1,164 P =
Diastolic blood pressure (mean±SD, mmHg) 77±5 84±8** 79±8 93±10***### 292 <0.001 17.9 <0.001
90-100, N (%) 1 (3) 7 (23) 11 (8) 55 (40)
>100, N (%) 0 (0) 1 (3) 2 (1) 31 (23)
Max, mmHg 90 100.5 103.5 129.5
Systolic blood pressure (mean±SD, mmHg) 131±11 145±14*** 133±15 157±15***### 486 <0.001 15.2 <0.001
160-180, N (%) 0 (0) 3 (10) 8 (6) 46 (34)
>180, N (%) 0 (0) 0 (0) 0 (0) 7 (5)
Max, mmHg 153 175.5 175 195.5
Heart rate (mean±SD, beats/min) 69±9 83±17*** 76±12 95±17*** 267 <0.001 2.38 NS
100-120, N (%) 0 (0) 1 (3) 3 (2) 33 (24)
>120, N (%) 0 (0) 2 (7) 0 (0) 13 (10)
Max, beats/min 95 133.5 116.5 145
Body temperature (mean±SD, °C) 37.0±0.3 37.2±0.3 37.4±0.5 37.7±0.5*** 44.4 <0.001 2.43 NS
38-39, N (%) 0 (0) 0 (0) 17 (13) 39 (29)
>39, N (%) 0 (0) 0 (0) 0 (0) 2 (1)
Max, °C 37.7 37.6 38.7 39.1
List of Complaints score
before (mean±SD, N) 1.1±1.5 1.4±2.1 1.5±2.2 1.4±1.8 0.01 NS 0.66 NS
acute, up to 6h (mean±SD, N) 1.6±2.1 5.6±4.5** 1.7±2.3 10.0±6.6***### 93.0 <0.001 11.9 <0.001
subacute, up to 24h (mean±SD, N) 0.9±1.5 2.9±4.1 0.9±2.2 5.7±5.6***## 35.5 <0.001 6.91 <0.01
N: number of subjects/complaints; SD: standard deviation; **P < 0.01, ***P < 0.001 compared to placebo, ##P < 0.01, ###P < 0.001 compared to 75mg; 
NS: not significant
Drug Drug x Dose
75 mg 125 mg
N = 30 N = 136
 
  
Table 3. Acute and subacute adverse effects of MDMA (total N = 166)
acute subacute acute subacute
0h up to 6h 24h 0h up to 6h 24h
N (%) N (%) N (%) N (%) N (%) N (%)
Lack of appetite 2 (1) 3 (2) 1 (1) 4 (2) 98 (59)*** 52 (31)***
Dry mouth 1 (1) 3 (2) 3 (2) 1 (1) 91 (55)*** 37 (23)***
Difficulty concentrating 6 (4) 10 (6) 4 (2) 5 (3) 76 (46)*** 35 (22)***
Cold feet 8 (5) 7 (4) 2 (1) 10 (6) 69 (42)*** 10 (6)*
Sweating 2 (1) 0 (0) 0 (0) 0 (0) 68 (41)*** 7 (4)*
Bruxisma 2 (2) 1 (1) 1 (1) 3 (2) 54 (40)*** 19 (14)***
Restless legs 1 (1) 2 (1) 2 (1) 2 (1) 62 (37)*** 12 (7)*
Dizziness 2 (1) 2 (1) 3 (2) 5 (3) 57 (34)*** 12 (7)*
Hot flushs 1 (1) 0 (0) 0 (0) 1 (1) 52 (31)*** 12 (7)***
Headache 9 (5) 27 (16) 25 (15) 8 (5) 42 (25) 55 (33)***
Heart palpitation 1 (1) 2 (1) 1 (1) 1 (1) 40 (24)*** 11 (7)**
Lack of energy 9 (5) 23 (14) 5 (3) 8 (5) 38 (23)* 49 (30)***
Nausea 3 (2) 2 (1) 1 (1) 2 (1) 19 (11)*** 9 (6)*
Anxiety 0 (0) 0 (0) 0 (0) 2 (1) 9 (6)** 3 (2)




Table 4. Chronic effects of MDMA on kidney and liver function and blood cell counts
Screening End of Study
Kidney and liver function t P =
Creatinine (normal: <97 µM)
mean±SD, µM (range) 74±13 (47-115) 73±12 (47-108) 1.89 NS
Glomerular filtration rate CCR (normal: >90 ml/min)
mean±SD, ml/min (range) 122±22 (70-202) 125±24 (64-220) -1.95 NS
Aspartate aminotransaminase (normal: <34 U/l)
mean±SD, U/l (range) 25±7 (14-64) 26±11 (9-131) -0.93 NS
Alanine aminotransferase (normal: <59 U/I)
mean±SD, U/l (range) 19±9 (6-64) 20±10 (5-82) -0.44 NS
ƴ-glutamyl transpeptidase (normal: <68 U/I)
mean±SD, U/l (range) 19±8 (7-56) 18±8 (7-51) 2.73 <0.01
Blood cell counts
White blood cells (normal: 3.5-10.0 x109/l)
mean±SD, x109/l (range) 6.6±1.8 (3.2-14.6) 6.4±1.8 (2.6-16.4) 1.54 NS
Red blood cells (normal: 4.2-6.3 x1012/l)
mean±SD, x1012/l (range) 4.7±0.4 (3.8-6.1) 4.6±0.4 (3.8-5.8) 4.77 < 0.001
Hemoglobin (normal: 120-180 g/l /)
mean±SD, g/l (range) 144±12 (121-174) 140±14 (106-181) 6.33 < 0.001
Thrombocytes (normal: 150-450 x109/l)
mean±SD, x109/l (range) 263±53 (145-438) 276±56 (164-481) -4.27 < 0.001












Clonidine +   
125mg MDMA
Carvedilol +   
125mg MDMA







MDMA                     
+ other drug
Drug dose 16 mg 120 mg 0.15 mg 50 mg 20 mg 60 mg 1'650 mg
N = 16 N = 16 N = 16 N = 16 N = 16 N = 16 N = 16 N = 112
Diastolic blood pressure (mean±SD, mmHg) 95±9 89±10 94±10 88±12 83±10 95±7 95±6 91±10
90-100, N (%) 6 (38) 7 (44) 5 (31) 2 (13) 2 (13) 9 (56) 11 (69) 47 (42)
>100, N (%) 5 (31) 2 (13) 5 (31) 3 (19) 1 (6) 3 (19) 3 (19) 27 (24)
Max, mmHg 107.5 103.5 113.5 118.5 100.5 109 103.5 118.5
Systolic blood pressure (mean±SD, mmHg) 154±13 144±11 154±18 136±16 147±17 159±12 160±13 151±16
160-180, N (%) 6 (38) 1 (6) 3 (19) 2 (13) 5 (31) 8 (50) 8 (50) 36 (32)
>180, N (%) 0 (0) 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 1 (6) 6 (5)
Max, mmHg 171 162 200 162 173 178 187 200
Heart rate (mean±SD, beats/min) 99±13 78±10 95±24 80±10 102±16 107±18 93±16 94±19
100-120, N (%) 7 (44) 1 (6) 1 (6) 0 (0) 7 (44) 5 (31) 7 (44) 29 (26)
>120, N (%) 0 (0) 0 (0) 4 (25) 0 (0) 2 (13) 4 (25) 1 (6) 11 (10)
Max, beats/min 119 103 141.5 97.5 132 146 120 146
Body temperature (mean±SD, °C) 37.5±0.3 37.5±0.5 37.7±0.4 37.5±0.5 36.8±0.4 38±0.6 37.8±0.6 37.5±0.6
38-39, N (%) 2 (13) 2 (13) 4 (25) 3 (19) 0 (0) 9 (56) 3 (19) 31 (28)
>39, N (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (13) 2 (2)
Max, °C 38.1 38.8 38.6 38.5 37.3 38.8 39.1 39.1
N: number of subjects; SD: standard deviation
 
  
Supplementary Table S2.  List of acute and subacute adverse effects of different MDMA doses
N = 30
acute subacute acute subacute
0h up to 6h 24h 0h up to 6h 24h
N (%) N (%) N (%) N (%) N (%) N (%)
Lack of appetite 0 (0) 2 (7) 0 (0) 0 (0) 13 (43)## 4 (13)
Dry mouth 0 (0) 0 (0) 0 (0) 0 (0) 9 (30)## 4 (13)
Difficulty concentrating 0 (0) 1 (3) 1 (3) 1 (3) 7 (23) 4 (13)
Cold feet 2 (7) 0 (0) 0 (0) 3 (10) 9 (30)## 1 (3)
Sweating 0 (0) 0 (0) 0 (0) 0 (0) 6 (20)# 1 (3)
Bruxism 1 (3) 1 (3) 1 (3) 2 (7) 5 (17) 1 (3)
Restless legs 0 (0) 0 (0) 0 (0) 0 (0) 7 (23)# 1 (3)
Dizziness 0 (0) 0 (0) 1 (3) 2 (7) 8 (27)## 2 (7)
Hot flushs 1 (3) 0 (0) 0 (0) 0 (0) 5 (17) 1 (3)
Headache 3 (10) 5 (17) 5 (17) 4 (13) 4 (13) 6 (20)
Heart palpitation 0 (0) 0 (0) 0 (0) 0 (0) 5 (17) 0 (0)
Lack of energy 1 (3) 5 (14) 1 (3) 1 (3) 4 (13) 4 (13)
Nausea 0 (0) 1 (3) 0 (0) 0 (0) 3 (10) 0 (0)
Anxiety 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
N = 136
acute subacute acute subacute
0h up to 6h 24h 0h up to 6h 24h
N (%) N (%) N (%) N (%) N (%) N (%)
Lack of appetite 2 (1) 1 (1) 1 (1) 3 (2) 85 (63)### 47 (35)*###
Dry mouth 1 (1) 3 (2) 3 (2) 1 (1) 82 (60)**### 33 (24)###
Difficulty concentrating 6 (4) 9 (7) 3 (2) 4 (3) 69 (51)*### 31 (23)###
Cold feet 6 (4) 7 (5) 2 (1) 7 (5) 61 (45)### 9 (7)#
Sweating 2 (1) 0 (0) 0 (0) 1 (1) 63 (46)*### 7 (5)#
Bruxisma 1 (1) 0 (0) 0 (0) 2 (1) 49 (47)**### 18 (18)###
Restless legs 1 (1) 2 (1) 2 (1) 3 (1) 55 (40)### 11 (8)#
Dizziness 2 (1) 2 (1) 2 (1) 3 (2) 48 (35)### 10 (7)#
Hot flushs 0 (0) 0 (0) 0 (0) 2 (1) 47 (35)### 11 (8)###
Headache 6 (4) 22 (16) 20 (15) 4 (3) 38 (28)# 49 (36)###
Heart palpitation 1 (1) 2 (1) 1 (1) 1 (1) 35 (26)### 11 (8)#
Lack of energy 8 (6) 18 (13) 4 (3) 7 (5) 34 (25)## 45 (33)*###
Nausea 3 (2) 1 (1) 1 (1) 2 (1) 16 (12)### 9 (7)#
Anxiety 0 (0) 0 (0) 0 (0) 1 (1) 9 (7)## 3 (2)
MDMA (125mg)Placebo (125mg)
Placebo (75mg) MDMA (75mg)
N: number of subjects/complaints; aN = 104, *P < 0.05, **P < 0.01 compared to 75mg, #P < 0.05, ##P < 0.01, ###P < 
0.001 compared to placebo (Fisher's exact test)
 
